Author
Listed:
- Yan Ye
(School of Medicine and Public Health, University of Newcastle
Anhui Medical University)
- Lei Jin
(Melanoma Institute Australia
Immunology and Oncology Unit, Kolling Institute for Medical Research, University of Sydney)
- James S. Wilmott
(Melanoma Institute Australia
Discipline of Pathology, University of Sydney
Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital)
- Wang Lai Hu
(Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China)
- Benafsha Yosufi
(Melanoma Institute Australia
Discipline of Pathology, University of Sydney
Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital)
- Rick F. Thorne
(Cancer Research Unit, University of Newcastle)
- Tao Liu
(Children’s Cancer Institute Australia for Medical Research, University of New South Wales)
- Helen Rizos
(Melanoma Institute Australia
Westmead Institute for Cancer Research, Westmead Hospital, University of Sydney at Westmead Millennium Institute)
- Xu Guang Yan
(Cancer Research Unit, University of Newcastle)
- Li Dong
(School of Medicine and Public Health, University of Newcastle
Melanoma Institute Australia)
- Kwang Hong Tay
(School of Medicine and Public Health, University of Newcastle
Melanoma Institute Australia)
- Hsin-Yi Tseng
(School of Medicine and Public Health, University of Newcastle
Melanoma Institute Australia)
- Su Tang Guo
(Shanxi Cancer Hospital and Institute)
- Charles E. de Bock
(Cancer Research Unit, University of Newcastle)
- Chen Chen Jiang
(School of Medicine and Public Health, University of Newcastle
Melanoma Institute Australia)
- Chun Yan Wang
(Shanxi Cancer Hospital and Institute)
- Mian Wu
(Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China)
- Lin Jie Zhang
(Anhui Medical University)
- Peter Hersey
(Melanoma Institute Australia
Immunology and Oncology Unit, Kolling Institute for Medical Research, University of Sydney)
- Richard A. Scolyer
(Melanoma Institute Australia
Discipline of Pathology, University of Sydney
Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital)
- Xu Dong Zhang
(School of Medicine and Public Health, University of Newcastle
Melanoma Institute Australia
Shanxi Cancer Hospital and Institute)
Abstract
Inositol polyphosphate 5-phosphatases can terminate downstream signalling of phosphatidylinositol-3 kinase; however, their biological role in the pathogenesis of cancer is controversial. Here we report that the inositol polyphosphate 5-phosphatase, phosphatidylinositol 4,5-bisphosphate 5-phosphatase, has a tumour suppressive role in melanoma. Although it is commonly downregulated in melanoma, overexpression of phosphatidylinositol 4,5-bisphosphate 5-phosphatase blocks Akt activation, inhibits proliferation and undermines survival of melanoma cells in vitro, and retards melanoma growth in a xenograft model. In contrast, knockdown of phosphatidylinositol 4,5-bisphosphate 5-phosphatase results in increased proliferation and anchorage-independent growth of melanocytes. Although DNA copy number loss is responsible for downregulation of phosphatidylinositol 4,5-bisphosphate 5-phosphatase in a proportion of melanomas, histone hypoacetylation mediated by histone deacetylases HDAC2 and HDAC3 through binding to the transcription factor Sp1 at the PIB5PA gene promoter appears to be another commonly involved mechanism. Collectively, these results establish the tumour suppressive role of phosphatidylinositol 4,5-bisphosphate 5-phosphatase and reveal mechanisms involved in its downregulation in melanoma.
Suggested Citation
Yan Ye & Lei Jin & James S. Wilmott & Wang Lai Hu & Benafsha Yosufi & Rick F. Thorne & Tao Liu & Helen Rizos & Xu Guang Yan & Li Dong & Kwang Hong Tay & Hsin-Yi Tseng & Su Tang Guo & Charles E. de Boc, 2013.
"PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma,"
Nature Communications, Nature, vol. 4(1), pages 1-15, June.
Handle:
RePEc:nat:natcom:v:4:y:2013:i:1:d:10.1038_ncomms2489
DOI: 10.1038/ncomms2489
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:4:y:2013:i:1:d:10.1038_ncomms2489. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.